Table 1.
Comparison between those who responded to treatment at M1 and M3 for socio-demographics and metabolic variablesa
| Total | M3 | |||||||
|---|---|---|---|---|---|---|---|---|
| RTT | NRTT | |||||||
| N = 169 | % | (Test statistics) pb | N = 98 | % | N = 71 | % | (Test statistic) p* | |
| Age, m (s.d.) | 42.0 (13.2) | 40.9 (13.1) | 43.6 (13.4) | (t = 1.32, df = 167) 0.19 | ||||
| Sex | ||||||||
| Females | 114/169 | 67.5 | 64/98 | 65.3 | 50/71 | 70.4 | (χ2 = 0.49, df = 1) 0.48 | |
| MDD duration (years), m (s.d.) | 9.7 (11.9) | 8.3 (10.8) | 11.7 (13.1) | (t = 1.81, df = 167) 0.07 | ||||
| HDRS score at baseline, m (s.d.) | 25.1 (4.9) | 25.7 (5.1) | 24.2 (4.5) | (t = −2.07, df = 167) 0.04 | ||||
| 5% weight gain at M1 | 29/169 | 17.2 | 17/98 | 17.4 | 12/71 | 16.9 | (χ2 = 0.01, df = 1) 0.94 | |
| Class of AD | ||||||||
| SSRI | 77/169 | 45.6 | 51/98 | 52.0 | 26/71 | 36.6 | (χ2 = 9.42, df = 3) 0.02 | |
| SNRI | 54/169 | 32.0 | 33/98 | 33.7 | 21/71 | 29.6 | ||
| TCA | 12/169 | 7.1 | 4/98 | 4.1 | 8/71 | 11.3 | ||
| Other | 26/169 | 15.3 | 10/98 | 10.2 | 16/71 | 22.5 | ||
| Dose at baseline | ||||||||
| Low | 13/159 | 8.2 | 4/97 | 4.1 | 9/62 | 14.5 | (χ2 = 5.60, df = 2) 0.05 | |
| Normal | 144/159 | 90.6 | 92/97 | 94.8 | 52/62 | 83.9 | ||
| High | 2/159 | 1.2 | 1/97 | 1.1 | 1/62 | 1.6 | ||
| MetSb | ||||||||
| M0, n/N | 0 | 0 |
Z = 3.31 <0.01 |
0 | 0 | 0 | 0 | |
| M3, n/N | 15/167 | 9.0 | 11/98 | 11.2 | 4/69 | 5.8 | (Z = 1.19) 0.24 | |
| M6, n/N | 12/120 | 10.0 | 10/79 | 12.7 | 1/38 | 2.6 | (Z = 7.93) <0.01 | |
| No. of MetS dysregulationsb | ||||||||
| M0, m (s.d.) | 1.0 (0.8) |
Z = 2.57 0.01 |
1.0 (0.8) | 1.1 (0.9) | (Z = −1.71) 0.09 | |||
| M3, m (s.d.) | 1.2 (1.0) | 1.1 (1.1) | 1.2 (0.9) | (Z = −0.17) 0.87 | ||||
| M6, m (s.d.) | 1.4 (1.1) | 1.3 (1.2) | 1.4 (1.0) | (Z = −0.63) 0.53 | ||||
| High WCb | ||||||||
| M0, n/N | 66/169 | 39.1 |
Z = 4.01 <0.01 |
34/98 | 34.7 | 32/71 | 45.1 | (Z = −3.06) 0.001 |
| M3, n/N | 79/168 | 47.0 | 40/98 | 40.8 | 39/70 | 55.7 | (Z = −4.64) <0.001 | |
| M6, n/N | 67/120 | 55.8 | 42/80 | 52.5 | 25/40 | 62.5 | (Z = −1.56) 0.12 | |
| High FPGb | ||||||||
| M0, n/N | 13/168 | 7.7 |
Z = 2.18 0.03 |
8/97 | 8.3 | 5/71 | 7.0 | (Z = 1.15) 0.25 |
| M3, n/N | 27/168 | 16.1 | 20/98 | 20.4 | 7/70 | 10.0 | (Z = 1.66) 0.10 | |
| M6, n/N | 18/119 | 15.1 | 14/79 | 17.7 | 4/40 | 10.0 | (Z = 2.42) 0.02 | |
| High BPb | ||||||||
| M0, n/N | 28/169 | 16.6 |
Z = 3.14 <0.01 |
15/98 | 15.3 | 13/71 | 18.3 | (Z = −0.49) 0.62 |
| M3, n/N | 43/169 | 25.4 | 28/98 | 28.6 | 15/71 | 21.1 | (Z = 1.37) 0.17 | |
| M6, n/N | 36/120 | 30.0 | 27/80 | 33.8 | 9/40 | 22.5 | (Z = 2.33) 0.02 | |
| High TGb | ||||||||
| M0, n/N | 19/169 | 11.2 |
Z = 2.03 0.04 |
11/98 | 11.2 | 8/71 | 11.3 | (Z = −0.01) 0.99 |
| M3, n/N | 22/169 | 13.0 | 14/98 | 14.3 | 8/71 | 11.3 | (Z = 2.01) 0.04 | |
| M6, n/N | 20/120 | 16.7 | 14/80 | 17.5 | 6/40 | 15.0 | (Z = 0.42) 0.68 | |
| Low HDLb | ||||||||
| M0, n/N | 47/169 | 27.8 |
Z = −2.42 0.02 |
28/98 | 28.6 | 19/71 | 26.8 | (Z = 0.30) 0.76 |
| M3, n/N | 24/168 | 14.3 | 10/97 | 10.3 | 14/71 | 19.7 | (Z = −2.65) <0.01 | |
| M6, n/N | 22/120 | 18.3 | 9/80 | 11.3 | 13/40 | 32.5 | (Z = −3.56) <0.01 | |
a
*p values were calculated using χ2 tests or Fisher exact test (dosage) for categorical variables and independent sample t test for continuous variable. p values for the metabolic parameters were calculated using univariate logistic regression adjusting for center effect.
b
p values reported from logistic regression mixed models accounting for the repeated measures of the metabolic variables over the 6 months follow-up.